RWJ-24517, a positive inotropic agent, has novel effects on action potentials in guinea pig myocardium.
RWJ-24517 is a positive inotropic agent whose mechanism of action is under investigation. We examined the effects of RWJ-24517 on guinea pig papillary muscle action potentials and myofilament response to Ca2+. RWJ-24517 increased the fast action potential duration (APD) in a dose-dependent fashion but had no effect on the myofilament response. Tetraethylammonium (TEA 10 mM), which in itself slightly prolonged the control AP, completely blocked the increase in APD75 (APD at 75% of repolarization) and suppressed the increase in APD25 induced by RWJ-24517 (10 microM). Verapamil (5 microM) had little effect on control APs but did decrease the prolongation of the AP induced by RWJ-24517. The increase in APD25 induced by RWJ-24517 was not completely blocked by TEA even with addition of verapamil or 4-aminopyridine (2 mM). RWJ-24517 enhanced Ca(2+)-dependent slow APs elicited by 0.1 microM isoproterenol in preparations depolarized by high extracellular K+ (25 mM), but had no effects on slow APs elicited by 10 mM TEA. These results suggest that the primary electrophysiologic effect of RWJ-24517 is a substantial AP prolongation, which appears to occur largely through a mechanism which is likely to involve inhibition of Ca(2+)-dependent K+ channels. It also appears to have additional effects on some other channels (possibly Na+ channels), which may contribute to the positive inotropic action of RWJ-24517.
Kawamura
A
A
Department of Physiology and Biophysics, University of Illinois at Chicago 60680.
Wahler
G M
GM
Solaro
R J
RJ
D008841:Actin Cytoskeleton / Q000187:drug effects* / Q000201:enzymology; D000200:Action Potentials / Q000187:drug effects; D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D005260:Female; D006168:Guinea Pigs; D008297:Male; D015122:Mercaptopurine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010210:Papillary Muscles / Q000187:drug effects* / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology*; D026902:Potassium Channel Blockers; D015222:Sodium Channels / Q000187:drug effects; D019789:Tetraethylammonium; D013757:Tetraethylammonium Compounds / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D002316:Cardiotonic Agents; D010879:Piperazines; D026902:Potassium Channel Blockers; D015222:Sodium Channels; D013757:Tetraethylammonium Compounds; C078816:carsatrin; D019789:Tetraethylammonium; D014700:Verapamil; D015122:Mercaptopurine; D000251:Adenosine Triphosphatases